Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04170283 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
A Phase 3 study of B-cell Malignancies, sponsored by BeiGene.
- Active
- Registry status
- Phase 3
- Development phase
- 955
- Enrollment target
- 20
- Study locations
NCT04170283: Active Phase 3 study of B-cell Malignancies, sponsored by BeiGene.
NCT04170283 is a Phase 3 study of B-cell Malignancies that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 955 participants, above the 175-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (446% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04170283, a Phase 3 study of B-cell Malignancies, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 955 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Primary Outcome
Safety as assessed by incidence of all treatment-emergent adverse events (TEAEs) and serious AEs (SAEs) and according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0)
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Tislelizumab
Study Locations (20)
Colorado
- Rocky Mountain Cancer Centers Centennial - Centennial
- Colorado Blood Cancer Institute - Denver
Florida
- Florida Cancer Specialists Fort Myers - Fort Myers
- Scri Florida Cancer Specialists North - St. Petersburg
New Jersey
- Summit Medical Group - Florham Park
- Atlantic Health System - Morristown
Oregon
- Oncology Associates of Oregon Willamette Valley Cancer Center - Eugene
- Oregon Health and Science University - Portland
Tennessee
- Scri Tennessee Oncology Chattanooga - Chattanooga
- Tennessee Oncology - Nashville
Arizona
- Banner Md Anderson Cancer Center - Gilbert
Arkansas
- Carti Cancer Center - Little Rock
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 955 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What the registry record for NCT04170283 still lists
NCT04170283 is an interventional study that assigns participants to a tested intervention. The registered 955 participants enrollment target is mid-sized for trials with a published cap, above the 175-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (446% higher).
The record links to 1 condition, with B-cell Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT04170283 names 20 study sites across 15 states, led by Colorado, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04170283 about?
NCT04170283 is a clinical study titled "Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies". The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
What is the current status of trial NCT04170283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 955 participants. The study started on 2020-01-16. Estimated completion is 2028-12.
What conditions does trial NCT04170283 study?
This clinical trial studies the following conditions: B-cell Malignancies.
What interventions are being tested in trial NCT04170283?
The interventions under investigation include: Zanubrutinib (DRUG), Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT04170283?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04170283 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RECRUITING · Phase 1
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI